Dyslipidemia is an increase in blood lipids. The excessive increase in levels of insulin may also lead to dyslipidemia.


LDL Cholesterol | HDL Cholesterol | NON-HDL Cholesterol | High Sensitivity C-Reactive Protein for Risk Assessment | Stratification of Dyslipidemia Risk | Advanced Lipoprotein Testing | Drugs for Treatment of Blood Lipoprotein Abnormalities

Market Statistics:

The global dyslipidemia drug market was worth US$ 11.8 billion in 2018 and is expected to grow at a CAGR of 3.5% from 2019 to 2027. 

North America is the leading contributor to the dyslipidemia medications market. According to the Centers for Disease Control and Prevention (CDC), over 95 million adults in the United States (55% of the population) had total cholesterol levels greater than 200 mg/dL as of 2016. Furthermore, total cholesterol levels higher than 240 mg/dL affect an estimated 29 million adults in the United States.